Immunotherapy
Finding ways to stimulate the body's immune system to help attack cancer cells is a growing area of research at The Institute of Cancer Research.
Clinical trials led by the ICR and our hospital partner The Royal Marsden have shown that the immunotherapy drug pembrolizumab can help extend the lives of some patients with advanced head and neck cancer, and prostate cancer.
The use of 'oncolytic' viruses, which can kill cancer cells both directly and by directing the immune system against them, is also an exciting area of research being explored by ICR researchers.
This page highlights recent news stories, blog posts and videos that concern immunotherapy research at the ICR.
Related pages
Latest ICR News
.jpg?sfvrsn=21a64ae3_1 "human-cells-with-acute-myelocytic-leukemia-(aml)")
New cancer test could predict, up to 10 years in advance, when treatment will be needed
Scientists have developed a new test that can decode when someone’s cancer first started growing and how fast it is growing, potentially allowing doctors to accurately predict when a patient will need treatment.
The ICR and The Royal Marsden team up with PureGym to support men with advanced prostate cancer to be more active
The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust have teamed up with Sir Chris Hoy and PureGym to launch a collaboration to encourage men with prostate cancer to be more active.